secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001213900-25-121497
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

New US law to materially hurt InMed's BayMedica cannabinoid business; core pharma programs unaffected
--------------------------------------------------------------------------------

- H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.
- BayMedica is evaluating alternative supply chain options to maintain regulatory compliance.
- InMed's pharmaceutical programs (INM-901 for Alzheimer's, INM-089 for AMD) are not affected by the legislation.
- Company warns of material negative impact on BayMedica's contribution to consolidated financial results.
- Act may be amended before Nov 12, 2026, but current form already enacted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025121497/0001213900-25-121497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025121497/ea0269687-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-121497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer